<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065622</url>
  </required_header>
  <id_info>
    <org_study_id>M14-033</org_study_id>
    <secondary_id>2013-001682-16</secondary_id>
    <nct_id>NCT02065622</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis</brief_title>
  <official_title>A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of two adalimumab dosing regimens for induction and&#xD;
      maintenance (standard and higher dosing) in achieving clinical remission in subjects with&#xD;
      moderately to severely active ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2014</start_date>
  <completion_date type="Actual">November 11, 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore &gt; 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore &gt; 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin &lt; 150 mg/kg at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore &gt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopy subscore provided by the central reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 [severe problem] to 7 [normal health]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">952</enrollment>
  <condition>Ulcerative Colitis (UC)</condition>
  <arm_group>
    <arm_group_label>Induction (Main Study + Japan Sub-study): I-SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction (Main Study + Japan Sub-study): I-HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance (Main Study + Japan Sub-study): M-SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance (Main Study + Japan Sub-study): M-HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance (Main Study): TDM Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Induction (Main Study + Japan Sub-study): I-HD</arm_group_label>
    <arm_group_label>Induction (Main Study + Japan Sub-study): I-SD</arm_group_label>
    <arm_group_label>Maintenance (Main Study + Japan Sub-study): M-HD</arm_group_label>
    <arm_group_label>Maintenance (Main Study + Japan Sub-study): M-SD</arm_group_label>
    <arm_group_label>Maintenance (Main Study): TDM Regimen</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Induction (Main Study + Japan Sub-study): I-SD</arm_group_label>
    <arm_group_label>Maintenance (Main Study + Japan Sub-study): M-SD</arm_group_label>
    <arm_group_label>Maintenance (Main Study): TDM Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy&#xD;
             during Screening period.&#xD;
&#xD;
          -  Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite&#xD;
             concurrent or prior treatment with a full and adequate course, in the opinion of the&#xD;
             Investigator, with oral corticosteroids or immunosuppressants or both. Mayo Score is&#xD;
             confirmed by central reader.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with Crohn's disease (CD) or indeterminate colitis (IC).&#xD;
&#xD;
          -  Current diagnosis of fulminant colitis and/or toxic megacolon.&#xD;
&#xD;
          -  Subjects with disease limited to the rectum (ulcerative proctitis) during the&#xD;
             screening endoscopy.&#xD;
&#xD;
          -  Chronic recurring infections or active tuberculosis (TB).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Specialists of the Southeast /ID# 127844</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd /Id# 122313</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Resear /ID# 122180</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Ctr CT /ID# 122179</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Florida /ID# 170619</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of South Florida,LLC /ID# 170309</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group Naples /ID# 127806</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shafran Gastroenterology Ctr /ID# 122320</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastro Assoc /ID# 122336</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Assoc of Central GA /ID# 122318</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine /ID# 122183</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 122302</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital /ID# 135955</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Ctr. LLC /ID# 141655</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105-6800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Med Ctr /ID# 169734</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGG Group, Inc.Chevy Chase Clinical Research /ID# 122238</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals /ID# 122240</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 122244</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr for Digest and Liver Dis /ID# 122182</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Long Island CRA /ID# 122177</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Med Mt. Sinai /ID# 127047</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastro Hepatology /ID# 122235</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC /ID# 122157</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Res /ID# 122304</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Gastroenterology, Inc. /ID# 127804</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro United of Tulsa /ID# 125436</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic- Gastro West /ID# 135273</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC /ID# 122331</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Institute for Clinica /ID# 129009</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One /ID# 122339</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Med Ctr /ID# 125496</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute /ID# 170616</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044-2208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic Research /ID# 171150</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024-2420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research /ID# 125396</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consul /ID# 141677</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consul /ID# 141678</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute /ID# 126147</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah /ID# 122333</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New River Valley Research Inst /ID# 127801</name>
      <address>
        <city>Christiansburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington /ID# 169721</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WI Center for Advanced Res /ID# 122178</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; the Medical College of Wisconsin /ID# 122261</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Elisabethinen Linz GmbH /ID# 127184</name>
      <address>
        <city>Linz</city>
        <state>Oberoesterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien /ID# 127186</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordination Hainburg an der Don /ID# 127185</name>
      <address>
        <city>Hainburg An Der Donau</city>
        <zip>2410</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Innere Medizin 1 /ID# 125944</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Barmherzigen Brueder /ID# 127183</name>
      <address>
        <city>St Veit An Der Glan</city>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas /ID# 127187</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 126739</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege /ID# 126740</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary /ID# 125715</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre /ID# 125713</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Regional Health Autho /ID# 125712</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qe Ii Hsc /Id# 127045</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre /ID# 127055</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 126590</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Digestive Disease Asso /ID# 127075</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC /ID# 127046</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK s.r.o. /ID# 127188</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISCARE a.s. /ID# 127837</name>
      <address>
        <city>Praha 9</city>
        <zip>190 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital /ID# 127191</name>
      <address>
        <city>Herlev</city>
        <state>Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionhospital Silkeborg /ID# 127190</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez /ID# 127197</name>
      <address>
        <city>Lille CEDEX</city>
        <state>Hauts-de-France</state>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hôpital Brabois Adultes /ID# 127196</name>
      <address>
        <city>Vandoeuvre les Nancy CEDEX</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie /ID# 127194</name>
      <address>
        <city>Amiens CEDEX 1</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing /ID# 127848</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon /ID# 127861</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Albet Michal /ID# 127195</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint ELOI /ID# 169007</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice /ID# 127193</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne, Hopital Nord /ID# 134490</name>
      <address>
        <city>SAINT-ETIENNE Cedex 1</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil /ID# 127192</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Regensburg /ID# 201265</name>
      <address>
        <city>Ratisbon</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt /ID# 170300</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein, Campus Kiel, Klinik furer Innere Medizin /ID# 127199</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 127203</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mross, Berlin, DE /ID# 127201</name>
      <address>
        <city>Berlin</city>
        <zip>10318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrostudien GbR /ID# 169246</name>
      <address>
        <city>Berlin</city>
        <zip>D-10825</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum Hamburg /ID# 127198</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena /ID# 127205</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EUGASTRO GmbH /ID# 127202</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Magdeburg /ID# 127200</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Campus Research GbR /ID# 126743</name>
      <address>
        <city>Munster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont I. sz. Belgyogyaszati Klinika /ID# 127209</name>
      <address>
        <city>Pécs</city>
        <state>Pecs</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Elhizastudomanyi KKft. /ID# 126589</name>
      <address>
        <city>Budapest</city>
        <zip>1124</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pannonia Maganorvosi Centrum Kft. /ID# 127207</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem /ID# 127208</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 127212</name>
      <address>
        <city>Petakh Tikva</city>
        <state>Tel-Aviv</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 201365</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center /ID# 127213</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital /ID# 127211</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center /ID# 127210</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico S.Orsola-Malpighi /ID# 129322</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini /ID# 127216</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli /ID# 127217</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 127138</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBD Center - IRCCS Istituto Clinico Humanitas /ID# 127215</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili /ID# 127236</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Padova /ID# 127214</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Villa Sofia-C /ID# 129323</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Univ Tor Vergata /ID# 129321</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo /ID# 127811</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital /ID# 124517</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokoyama IBD Clinic /ID# 151560</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center /ID# 124497</name>
      <address>
        <city>Sakura-shi</city>
        <state>Chiba</state>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Chikushi Hospital /ID# 124155</name>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <zip>818-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital /ID# 124495</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital /ID# 125275</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hidaka Clinic of Coloproctology /ID# 125477</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>839-0809</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital /ID# 124496</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 124480</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aoyama Clinic /ID# 127836</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine College Hospital /Id# 127539</name>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital /ID# 137694</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COLO-PROCTOLOGY CENTER Matsushima Clinic /ID# 148423</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>220-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Susaki Kuroshio Hospital /ID# 125202</name>
      <address>
        <city>Susaki-shi</city>
        <state>Kochi</state>
        <zip>785-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daiichi Hos /ID# 127540</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>605-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital /ID# 126451</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center /ID# 128875</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital /ID# 127675</name>
      <address>
        <city>Otsu-shi</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu South Hospital /ID# 124481</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>430-0846</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Hospital of Tokyo Medical and Dental University /ID# 128315</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato Univ Kitasato Inst Ho /ID# 127001</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital /ID# 148184</name>
      <address>
        <city>Mitaka-shi</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University /ID# 124635</name>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Yamate Medical Center /ID# 125201</name>
      <address>
        <city>Tokyo</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum /ID# 126741</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Nr 2 im. dr J.Biziela w Bydgoszczy /ID# 127141</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.M. Szpital Swietej Rodziny /ID# 127838</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia MDM /ID# 170303</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoterapia PFG Sp. z.o.o. /ID# 126513</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-653</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Gdynia /ID# 170301</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ All-Medicus /ID# 128740</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-659</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H-T.Centrum Medyczne-Endoterapia /ID# 170305</name>
      <address>
        <city>Tychy</city>
        <state>Slaskie</state>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne LukaMed Joanna Luka /ID# 170302</name>
      <address>
        <city>Chojnice</city>
        <zip>89-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Sw. Lukaza /ID# 126515</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyczno Lecznicze Barska /ID# 170304</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-Med Centra Kliniczne Pulawy /ID# 127219</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Vivamed /ID# 127218</name>
      <address>
        <city>Warsaw</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni /ID# 127839</name>
      <address>
        <city>Sector 2</city>
        <state>Bucuresti</state>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMDTA Neomed SRL /ID# 127142</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta /ID# 125418</name>
      <address>
        <city>Cluj</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tvm Med Serv Srl /Id# 127221</name>
      <address>
        <city>Cluj</city>
        <zip>400132</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Dr. Fratila SRL, Specialitatea Medicina Interna /ID# 127002</name>
      <address>
        <city>Oradea</city>
        <zip>410167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salvo-San-Ciobanca SRL /ID# 127140</name>
      <address>
        <city>Zalau</city>
        <zip>450117</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologicke centrum ASSIDUO a IBD centrum /ID# 127222</name>
      <address>
        <city>Bratislava</city>
        <zip>831 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologicka Ambulancia /ID# 125632</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna Nemocnica s poliklinikou Lucenec /ID# 127322</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante /ID# 129261</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 138147</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ferrol /ID# 127840</name>
      <address>
        <city>Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Dr. Negrin /ID# 127841</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ de la Princesa /ID# 135828</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon /ID# 127224</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ 12 de Octubre /ID# 129257</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 127223</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Clin Univ de Valencia /ID# 170306</name>
      <address>
        <city>València</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Clin Univ Lozano Blesa /ID# 129255</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen /ID# 127843</name>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich /ID# 127842</name>
      <address>
        <city>Zurich</city>
        <state>Zuerich</state>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI National Institute of Therapy named by L.T. Malaya /ID# 127231</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Institution Kherson City Clinical Hospital named after le.le. Karabelesh /ID# 127233</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital #8 /ID# 127235</name>
      <address>
        <city>Kiev</city>
        <zip>04201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv City Clinical Hospital NO.4 /ID# 127232</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNPE City Hospital No.6 of Zaporizhzhia City Counsil /ID# 127137</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hampshire County Hosp /ID# 169250</name>
      <address>
        <city>Winchester</city>
        <state>Hampshire</state>
        <zip>SO22 5DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Univ Hosp /ID# 127139</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital /ID# 204801</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mark's Hospital /ID# 127226</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust /ID# 127225</name>
      <address>
        <city>Hull</city>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust The John Radcliffe Hospital /ID# 129324</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital /ID# 127228</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Tr /ID# 127227</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>September 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02065622/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02065622/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study included a Main Study (120 sites in 19 countries) and a Japan Sub-Study (22 sites in Japan).&#xD;
After a 3-week screening period, participants were randomized 3:2 to an 8-week double-blind (DB) Induction Period with 2 adalimumab dosing regimens (Induction Standard Dose [I-SD] or Induction Higher Dose [I-HD]).</recruitment_details>
      <pre_assignment_details>At Week 8, participants in Main Study were re-randomized (2:2:1) into 44-week DB Maintenance Period with 3 adalimumab dosing regimens (M-SD, M-HD, or an exploratory Therapeutic Drug Monitoring [TDM] Regimen). Participants in Japan Sub-study were re-randomized (1:1) into 44-week DB Maintenance Period with 2 adalimumab dosing regimens (M-SD, M-HD).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Induction (Main Study + Japan Sub-study): I-SD</title>
          <description>Induction Standard Dose (I-SD): Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
        </group>
        <group group_id="P2">
          <title>Induction (Main Study + Japan Sub-study): I-HD</title>
          <description>Induction Higher Dose (I-HD): Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
        </group>
        <group group_id="P3">
          <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
          <description>Maintenance Standard Dose (M-SD): Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
          <description>Maintenance Higher Dose (M-HD): Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Maintenance (Main Study): TDM Regimen</title>
          <description>Exploratory Therapeutic Drug Monitoring (TDM) Regimen: Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore assessments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="379"/>
                <participants group_id="P2" count="573"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in Main Study</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="512"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in Japan Sub-Study</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="514"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requires Alternative/Prohibited Therapy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="345"/>
                <participants group_id="P4" count="350"/>
                <participants group_id="P5" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="221"/>
                <participants group_id="P4" count="246"/>
                <participants group_id="P5" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requires Alternative/Prohibited Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction (Main Study + Japan Sub-study): I-SD</title>
          <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
        </group>
        <group group_id="B2">
          <title>Induction (Main Study + Japan Sub-study): I-HD</title>
          <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="379"/>
            <count group_id="B2" value="573"/>
            <count group_id="B3" value="952"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="13.14"/>
                    <measurement group_id="B2" value="40.5" spread="12.89"/>
                    <measurement group_id="B3" value="40.4" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="484"/>
                    <measurement group_id="B3" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Not Specified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="321"/>
                    <measurement group_id="B2" value="484"/>
                    <measurement group_id="B3" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="573"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="460"/>
                    <measurement group_id="B3" value="774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Full Mayo Score (FMS)</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease).</description>
          <population>participants with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="570"/>
                    <count group_id="B3" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.69" spread="1.509"/>
                    <measurement group_id="B2" value="8.87" spread="1.571"/>
                    <measurement group_id="B3" value="8.80" spread="1.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FMS: Rectal Bleeding Subscore</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease).</description>
          <population>participants with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="379"/>
                    <count group_id="B2" value="570"/>
                    <count group_id="B3" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.68" spread="0.955"/>
                    <measurement group_id="B2" value="1.75" spread="0.967"/>
                    <measurement group_id="B3" value="1.72" spread="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore &gt; 1.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore &gt; 1.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.269</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.447</p_value>
            <method>Breslow-Day test</method>
            <method_desc>Breslow-Day test of homogeneity across strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.301</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.502</p_value>
            <method>Breslow-Day test</method>
            <method_desc>Breslow-Day test of homogeneity across strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore &gt; 1.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Responder population (I-ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore &gt; 1.</description>
          <population>ITT-Responder population (I-ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="30.1"/>
                    <measurement group_id="O4" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>20.6</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Breslow-Day test</method>
            <method_desc>Breslow-Day test of homogeneity across strata.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>Breslow-Day test</method>
            <method_desc>Breslow-Day test of homogeneity across strata.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="26.9"/>
                    <measurement group_id="O4" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin &lt; 150 mg/kg at Week 8</title>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin &lt; 150 mg/kg at Week 8</title>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="26.9"/>
                    <measurement group_id="O4" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.300</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8</title>
        <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8</title>
          <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                    <measurement group_id="O2" value="67.2"/>
                    <measurement group_id="O3" value="60.7"/>
                    <measurement group_id="O4" value="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>13.1</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="38.8"/>
                    <measurement group_id="O4" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>15.1</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="13.1"/>
                    <measurement group_id="O3" value="10.0"/>
                    <measurement group_id="O4" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8</title>
        <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8</title>
          <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="71.3"/>
                    <measurement group_id="O3" value="63.1"/>
                    <measurement group_id="O4" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>8.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8</title>
        <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.</description>
        <time_frame>Week 8</time_frame>
        <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction (Main Study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O2">
            <title>Induction (Main Study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
          <group group_id="O3">
            <title>Induction (Main Study + Japan Sub-study): I-SD</title>
            <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.</description>
          </group>
          <group group_id="O4">
            <title>Induction (Main Study + Japan Sub-study): I-HD</title>
            <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8</title>
          <description>The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.</description>
          <population>Induction Study Intent-to-Treat (ITT) set: all participants who were randomized at Baseline. Non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="512"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="61.1"/>
                    <measurement group_id="O3" value="57.5"/>
                    <measurement group_id="O4" value="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel test adjusted for previous infliximab use and baseline corticosteroid use.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.456</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
            <estimate_desc>Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Responder population (I-ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.</description>
          <population>ITT-Responder population (I-ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="51.3"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>20.8</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>20.5</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.</description>
        <time_frame>Week 52</time_frame>
        <population>I-ITT-RP: participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid use at Baseline. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.</description>
          <population>I-ITT-RP: participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid use at Baseline. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="74.7"/>
                    <measurement group_id="O3" value="54.4"/>
                    <measurement group_id="O4" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</method_desc>
            <param_type>Adjusted risk difference</param_type>
            <param_value>21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.6</ci_lower_limit>
            <ci_upper_limit>35.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>19.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.6</ci_lower_limit>
            <ci_upper_limit>32.7</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore &gt; 1.</description>
        <time_frame>Week 52</time_frame>
        <population>I-ITT-RP: participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid use at Baseline. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore &gt; 1.</description>
          <population>I-ITT-RP: participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid use at Baseline. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="38.9"/>
                    <measurement group_id="O3" value="28.2"/>
                    <measurement group_id="O4" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>23.8</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopy subscore provided by the central reader.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Remitter (ITT-RM) Population included all participants in the ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopy subscore provided by the central reader.</description>
          <population>ITT-Remitter (ITT-RM) Population included all participants in the ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>15.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>38.2</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.312</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Remitter (ITT-RM) Population included all participants in the ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.</description>
          <population>ITT-Remitter (ITT-RM) Population included all participants in the ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4"/>
                    <measurement group_id="O2" value="64.3"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.272</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>12.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>34.4</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.600</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>25.2</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-RM Population: participants in ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid use at Baseline. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
          <population>ITT-RM Population: participants in ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid use at Baseline. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="77.8"/>
                    <measurement group_id="O3" value="56.3"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>23.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>49.9</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>15.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>38.4</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-RM Population: all participants in the ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid usage. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
          <population>ITT-RM Population: all participants in the ITT population who achieved Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants with steroid usage. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="37.5"/>
                    <measurement group_id="O4" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>20.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>47.3</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>36.8</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Responder population (ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.</description>
          <population>ITT-Responder population (ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, the TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                    <measurement group_id="O2" value="66.4"/>
                    <measurement group_id="O3" value="62.6"/>
                    <measurement group_id="O4" value="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.422</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.513</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Non-Responder (ITT-NRP) Population: all participants in ITT who did not achieve Week 8 response based on the Full Mayo Score utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
          <population>ITT-Non-Responder (ITT-NRP) Population: all participants in ITT who did not achieve Week 8 response based on the Full Mayo Score utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="182"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="12.1"/>
                    <measurement group_id="O4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.351</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>11.4</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.292</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Non-Remitter (ITT-NRM) Population: all participants in ITT who did not achieve Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1.</description>
          <population>ITT-Non-Remitter (ITT-NRM) Population: all participants in ITT who did not achieve Week 8 remission based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="17.0"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.121</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-RP: participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants who were remitters at Week 8. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
          <population>ITT-RP: participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Participants who were remitters at Week 8. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>17.9</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>17.9</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Remitter (ITT-RM) Population: all participants in ITT who achieved Week 8 remission based on the Full Mayo Score utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore &gt; 1. Endoscopic remission is defined as an endoscopy subscore of 0.</description>
          <population>ITT-Remitter (ITT-RM) Population: all participants in ITT who achieved Week 8 remission based on the Full Mayo Score utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="47.6"/>
                    <measurement group_id="O3" value="42.2"/>
                    <measurement group_id="O4" value="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.903</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.0</ci_lower_limit>
            <ci_upper_limit>23.8</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.901</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.8</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Responder population (ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.</description>
          <population>ITT-Responder population (ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                    <measurement group_id="O2" value="69.7"/>
                    <measurement group_id="O3" value="62.6"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>18.4</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>19.1</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52</title>
        <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 [severe problem] to 7 [normal health]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT-Responder population (ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance (Main Study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance (Main Study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
            <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
            <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52</title>
          <description>The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy [confirmed by a central reader], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 [severe problem] to 7 [normal health]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.</description>
          <population>ITT-Responder population (ITT-RP): all participants in the Induction ITT population who achieve Week 8 response based on the FMS utilizing the endoscopy subscore provided by the central reader. Non-responder imputation. Per protocol, TDM Regimen arm was used to analyze exploratory outcome measures only (and therefore is not included).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="163"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="61.2"/>
                    <measurement group_id="O3" value="55.2"/>
                    <measurement group_id="O4" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted risk difference, 95% confidence interval for the difference in the proportions between the treatment groups and P-value were calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for induction treatment regimen and week 8 remission status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.440</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted risk difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>14.8</ci_upper_limit>
            <estimate_desc>Risk difference = Adalimumab 40mg EW - Adalimumab 40mg EOW.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>See time frame specifics detailed for each reporting group in their respective descriptions below. Participants were contacted 70 days following study drug discontinuation for an assessment of any new or ongoing adverse events, except those participants who continued on adalimumab therapy after the end of study participation.</time_frame>
      <desc>Treatment-emergent adverse events (TEAEs) are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction (Main Study + Japan Sub-study): I-SD</title>
          <description>Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.&#xD;
TEAEs during induction period: events with an onset date on or after first dose date of study drug in induction period and up to 70 days after last dose date of the study drug in induction period and prior to first dose date of study drug in maintenance period. Mean duration of treatment was 57.5 days.</description>
        </group>
        <group group_id="E2">
          <title>Induction (Main Study + Japan Sub-study): I-HD</title>
          <description>Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4 and 40 mg at Week 6.&#xD;
TEAEs during induction period: events with an onset date on or after first dose date of study drug in induction period and up to 70 days after last dose date of the study drug in induction period and prior to first dose date of study drug in maintenance period. Mean duration of treatment was 55.0 days.</description>
        </group>
        <group group_id="E3">
          <title>Maintenance (Main Study + Japan Sub-study): M-SD</title>
          <description>Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.&#xD;
TEAEs during maintenance period: events with an onset date on or after first dose date of study drug in maintenance period and up to 70 days after the last dose date of the study drug in maintenance period. Mean duration of treatment was 251.5 days.</description>
        </group>
        <group group_id="E4">
          <title>Maintenance (Main Study + Japan Sub-study): M-HD</title>
          <description>Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.&#xD;
TEAEs during maintenance period: events with an onset date on or after first dose date of study drug in maintenance period and up to 70 days after the last dose date of the study drug in maintenance period. Mean duration of treatment was 263.1 days.</description>
        </group>
        <group group_id="E5">
          <title>Maintenance (Main Study): TDM Regimen</title>
          <description>Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.&#xD;
TEAEs during maintenance period: events with an onset date on or after first dose date of study drug in maintenance period and up to 70 days after the last dose date of the study drug in maintenance period. Mean duration of treatment was 255.9 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="573"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="573"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="345"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="350"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="573"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYELID PTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>OPTIC ATROPHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ANOGENITAL DYSPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="379"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="573"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="345"/>
                <counts group_id="E4" events="21" subjects_affected="18" subjects_at_risk="350"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PORTOSPLENOMESENTERIC VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>EXTERNAL EAR CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PERINEAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PERITONSILLAR ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>STERNITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS OF INTRATHORACIC LYMPH NODES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MENISCUS INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>FIBROMATOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA IN SITU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE CERVIX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>MONONEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BINGE DRINKING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SINUS POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA NODOSUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>EXCESSIVE SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>LINEAR IGA DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>PEMPHIGOID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>SUBCORNEAL PUSTULAR DERMATOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>WOUND DRAINAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="573"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="573"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="345"/>
                <counts group_id="E4" subjects_affected="141" subjects_at_risk="350"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="379"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="573"/>
                <counts group_id="E3" events="70" subjects_affected="60" subjects_at_risk="345"/>
                <counts group_id="E4" events="58" subjects_affected="47" subjects_at_risk="350"/>
                <counts group_id="E5" events="29" subjects_affected="23" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="379"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="573"/>
                <counts group_id="E3" events="61" subjects_affected="47" subjects_at_risk="345"/>
                <counts group_id="E4" events="57" subjects_affected="46" subjects_at_risk="350"/>
                <counts group_id="E5" events="20" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="573"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="345"/>
                <counts group_id="E4" events="20" subjects_affected="19" subjects_at_risk="350"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="379"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="573"/>
                <counts group_id="E3" events="27" subjects_affected="23" subjects_at_risk="345"/>
                <counts group_id="E4" events="27" subjects_affected="23" subjects_at_risk="350"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="379"/>
                <counts group_id="E2" events="62" subjects_affected="48" subjects_at_risk="573"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E4" events="36" subjects_affected="22" subjects_at_risk="350"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="379"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="573"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="345"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="350"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

